公开(公告)号：US20210154183A1

公开(公告)日：2021-05-27

申请号：US17150099

申请日：2021-01-15

Applicant: Bristol-Myers Squibb Company

Inventor： Christopher Lee Mulligan ,  Justin Blake Bartlett ,  Michael Darron Robbins

IPC: A61K31/454 ,  A61K31/573 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00

Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.

公开(公告)号：US20160264670A1

公开(公告)日：2016-09-15

申请号：US15035080

申请日：2014-11-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Robert F Graziano ,  Michael Darron Robbins ,  Maria Jure-Kunkel

IPC: C07K16/28

CPC classification number: C07K16/2806 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2878 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/75

Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.

Abstract translation: 本文描述的本发明涉及用于增强抗CS1抗体与一种或多种免疫治疗剂组合的治疗功效的治疗剂量方案及其组合。

公开(公告)号：US10925867B2

公开(公告)日：2021-02-23

申请号：US15738412

申请日：2016-06-28

Applicant: Bristol-Myers Squibb Company

Inventor： Christopher Lee Mulligan ,  Justin Blake Bartlett ,  Michael Darron Robbins

IPC: A61K31/454 ,  A61K31/573 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00

Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.